Biosafety Risks and Transparency Deficits in EnteroMix: A Multivirus Oncolytic Therapy

EnteroMix is a Russian-developed multivirus oncolytic therapy currently in Phase I clinical trials. According to available public information, the formulation involves intravenous co-administration of four replication-competent enteroviruses: Coxsackievirus A21 (CVA21), Echovirus 7 (ECHO-7), Enterovirus B75 (EV-B75), and an IRES-switched poliovirus–rhinovirus chimera (PV-Russo). The use of multiple oncolytic viruses with distinct receptor specificities is, in principle, a promising strategy that could broaden the therapeutic window and enhance overall therapeutic efficacy. Different receptor tropisms can provide mechanistic synergy, allowing each virus to target distinct tumor niches and thereby strengthen the overall antitumor response.

However, enteroviruses are among the most recombinogenic RNA viruses known: they have high mutation rates, lack proofreading during replication, and frequently undergo intraspecies and sometimes even interspecies recombination when two related viruses infect the same cell. In nature, simultaneous infection of one host with four different enteroviruses is exceedingly rare, and co-infection of the same cell by multiple enteroviruses is even rarer. By contrast, EnteroMix intentionally introduces four replication-competent enteroviruses into the bloodstream at the same time, creating an artificial ecological niche with unprecedented opportunities for both mutation and recombination. This engineered co-circulation greatly increases the likelihood of generating novel recombinant genomes with unpredictable biological properties.

Although severe outcomes are uncommon, wild-type ECHO-7 and EV-B75 have been rarely associated with clinically significant disease, including aseptic meningitis, acute flaccid paralysis, encephalitis in infants and young children, and fatal infections in immunocompromised patients. In the absence of genomic transparency or strain-specific attenuation data, the co-administration of multiple clinically relevant enteroviruses raises serious concerns for public health safety, given the unresolved risks of viremia, neuroinvasion, and intra-host recombination that could generate novel pathogenic variants. If such recombinant enteroviruses were to arise during clinical use, they could seed new infectious outbreaks in Russia, with the potential for subsequent spread to other countries through routine travel and population movement. The history of enterovirus, influenza, and coronavirus outbreaks demonstrates that emergent viral variants can spread internationally with ease, underscoring the importance of robust biosafety safeguards. These concerns do not suggest wrongdoing; rather, they highlight a gap between current scientific knowledge of enterovirus biology and the regulatory framework governing this therapy.

Current documentation provides no evidence of compliance with WHO biosafety expectations for poliovirus-derived constructs, including genomic characterization, attenuation assessment, and shedding studies. Comprehensive disclosure and receptor-relevant preclinical validation are essential prerequisites before further human use; these data are not yet publicly available.

The concerns outlined here do not question the integrity of the developers or the scientific promise of multivirus oncolytic strategies. Rather, they highlight a critical gap between contemporary knowledge of enterovirus biology and the current regulatory framework governing oncolytic virotherapy in Russia. Addressing this gap is essential for ensuring both patient safety and broader public health protection.